GlassScriptPhysician profile
Luis I Becerra-Cabal
NPI 1164493649
$20,855.58
in general payments reported to CMS, 2019-2025
68 companies · $5,023 in 2025
The $5,023 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,488 · 2020: $1,440 · 2021: $1,867 · 2022: $3,266 · 2023: $4,234 · 2024: $3,537 · 2025: $5,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $1,525 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,170.83 |
| Consulting Fee | $1,525.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,391.86 | 2020-2025 | Qulipta, Botox, Ubrelvy |
| Pfizer INC. | $2,290.86 | 2023-2025 | |
| Ucb, INC. | $1,733.84 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $819.51 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $764.93 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $740.92 | 2020-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $724.53 | 2023-2025 | Rexulti, Nuedexta |
| Argenx US, INC. | $656.98 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $591.42 | 2019-2025 | Apokyn |
| Alexion Pharmaceuticals, INC. | $589.71 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $566.52 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $487.33 | 2019-2025 | |
| Lundbeck LLC | $484.71 | 2019-2025 | Vyepti, Rexulti |
| Allergan, INC. | $483.06 | 2019-2022 | |
| Biogen, INC. | $432.58 | 2019-2025 | Leqembi, Plegridy, Tysabri |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $429.48 | 2020-2025 | |
| Lilly USA, LLC | $399.70 | 2019-2024 | Emgality, Amyvid, Kisunla |
| Amgen INC. | $396.50 | 2019-2025 | Uplizna |
| Tanabe Pharma America, INC. | $320.92 | 2019-2025 | Radicava |
| Sunovion Pharmaceuticals INC. | $305.59 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $304.64 | 2019-2025 | Nuplazid |
| Abbott Laboratories | $303.99 | 2023-2024 | Infinity, Eterna |
| Ge Healthcare | $283.76 | 2019-2025 | |
| Acorda Therapeutics, INC | $273.48 | 2019-2024 | Inbrija, Ampyra |
| Adamas Pharmaceuticals, INC. | $263.73 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $249.87 | 2022 | |
| Janssen Biotech, INC. | $237.89 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $236.85 | 2021-2025 | Wainua |
| Biohaven Pharmaceuticals, INC. | $232.72 | 2020-2021 | |
| Kyowa Kirin, INC. | $223.64 | 2019-2024 | Nourianz |
| Upsher-Smith Laboratories LLC | $204.05 | 2019-2022 | |
| Boston Scientific Corporation | $191.44 | 2019-2023 | |
| Genzyme Corporation | $184.51 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $150.68 | 2022-2023 | Ponvory |
| Amneal Pharmaceuticals LLC | $149.49 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Microvention, INC. | $133.08 | 2025 | Web Aneurysm Embolization System |
| Neurelis, INC. | $130.84 | 2022-2024 | Valtoco |
| Novo Nordisk INC | $121.63 | 2025 | |
| Avion Pharmaceuticals | $115.98 | 2022-2023 | Dhivy |
| Idorsia Pharmaceuticals US INC | $115.06 | 2023 | Quviviq |
| Aquestive Therapeutics, INC. | $91.84 | 2022 | |
| Livanova USA, INC. | $86.61 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Axsome Therapeutics, INC. | $81.95 | 2025 | Symbravo |
| Supernus Pharmaceuticals, INC. | $71.18 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $66.67 | 2023-2024 | Ztlido |
| Ani Pharmaceuticals, INC. | $62.84 | 2023-2024 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $62.10 | 2023 | Gammagard |
| Merz Pharmaceuticals, LLC | $55.32 | 2023-2025 | Xeomin |
| Alnylam Pharmaceuticals INC. | $52.58 | 2022-2023 | Onpattro |
| Genentech USA, INC. | $50.72 | 2025 | Ocrevus, Ocrevus Zunovo |
| Vanda Pharmaceuticals INC. | $46.59 | 2024-2025 | Ponvory |
| Celgene Corporation | $46.06 | 2022-2024 | Zeposia |
| Impel Pharmaceuticals INC. | $43.42 | 2022-2023 | Trudhesa |
| Averitas Pharma INC. | $39.55 | 2023 | Qutenza |
| Octapharma USA, INC. | $38.31 | 2023-2024 | Panzyga |
| Greenwich Biosciences, INC. | $33.85 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.82 | 2022 | |
| Sumitomo Pharma America, INC. | $23.57 | 2023 | Aptiom |
| Avanir Pharmaceuticals, INC. | $20.79 | 2019 | |
| Horizon Therapeutics Plc | $19.22 | 2019 | |
| Grt US Holding, INC. | $18.94 | 2022 | |
| Corium, LLC | $17.05 | 2023 | Adlarity |
| Almatica Pharma LLC | $15.63 | 2023 | Gralise |
| Globus Medical, INC. | $15.08 | 2025 | Senza |
| Banner Life Sciences, LLC | $15.04 | 2024 | |
| Promius Pharma LLC | $15.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.54 | 2022 | |
| Currax Pharmaceuticals LLC | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Becerra-Cabal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.